Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06546332
Active, not recruiting Observational

Post Market Clinical Follow-Up KeriFuse®

NCT06546332 · tracked via the Priya Life Science France tracker
Sponsor
Keri Medical SA
Phase
Observational
Started
2022-07-05
Last updated
2026-08-12

Condition(s) studied

Arthritis

Investigational drug(s) / intervention(s)

KeriFuse®

KeriFuse®: The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.

Study summary

The general objective of this study is to evaluate the performances and the safety related to the KeriFuse® intramedullary arthrodesis implant and associated instrumentation used in accordance with their approved labelling and instruction for use. Performance and safety of KeriFuse® intramedullary arthrodesis implant will be established on short and middle-terms in regards to the implant life-cycle.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients ≥ 18 years, * Patients that will have a surgery using a KeriFuse® implant in accordance with the approved labelling and IFU. Exclusion Criteria: * Pregnant or nursing women, * Patients with intellectual disabilities who cannot follow the instructions of their surgeon, * Patients with a contraindication to surgery and more specifically to the implantation of KeriFuse®, * Patients with acute or chronic infections, local or systemic, * Patients with sensitivities or allergies to the implant components (Nickel, Titanium).

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Centre de la main du Pays d'Aix Aix-en-Provence France
Clinique de la Chataigneraie Beaumont France
Centre Ostéo Articulaire Fleming Bourgoin France
Clinique Saint François Nice France
Clinique Mutualiste Catalane Perpignan France
Clinique du Parc Périgueux France

More Keri Medical SA trials in France

Post Market Clinical Follow-Up TOUCH® CMC 1 Active, not recruiting
Post Market Clinical Follow-Up KeriFlex® Recruiting

Other trials for the same condition

The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06546332 on ClinicalTrials.gov ↗ ← All trials in France